The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

(VRS): Verbal Rating Scales; (BP-EP): Breakthrough or intense Episodic Pain; (CI): Confidence Interval. CB participated in the design of the study, performed the statistical analysis and drafted ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Pain intensity during and after cycling was measured using a numerical pain rating scale. Results The NSCLBP (FP) subjects were significantly more flexed (P=.018) at the lower lumbar spine during ...

LONDON, Jan 7 (Reuters) - There is a 30%-40% chance that France will see further negative credit rating moves this year unless the government can finally find a way to rein in its spending ...

This study, comparing NRS and VRS psychometric properties in the assessment of pain exacerbations, reveals a significantly higher discriminatory capability of NRS in distinguishing between ...